224 related articles for article (PubMed ID: 19393832)
1. Proteasome inhibitors in multiple myeloma.
Anderson KC
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S20-6. PubMed ID: 19393832
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Orlowski RZ
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
6. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Jagannath S; Dimopoulos MA; Lonial S
Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
[TBL] [Abstract][Full Text] [Related]
7. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
8. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
9. [Role of bortezomib in the treatment of multiple myeloma].
Gotoh A; Ohyashiki K
Nihon Rinsho; 2007 Dec; 65(12):2309-14. PubMed ID: 18069278
[TBL] [Abstract][Full Text] [Related]
10. The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.
Baumann P; Müller K; Mandl-Weber S; Leban J; Doblhofer R; Ammendola A; Baumgartner R; Oduncu F; Schmidmaier R
Br J Haematol; 2009 Mar; 144(6):875-86. PubMed ID: 19170678
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
12. The role of proteasome in malignant diseases.
Moran E; Nencioni A
J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors as therapeutics.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Essays Biochem; 2005; 41():205-18. PubMed ID: 16250907
[TBL] [Abstract][Full Text] [Related]
14. The proteasome: a worthwhile target for the treatment of solid tumours?
Milano A; Iaffaioli RV; Caponigro F
Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition and multiple myeloma.
Kanagasabaphy P; Morgan GJ; Davies FE
Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
[TBL] [Abstract][Full Text] [Related]
16. Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Olivier S; Robe P; Bours V
Biochem Pharmacol; 2006 Oct; 72(9):1054-68. PubMed ID: 16973133
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitors in cancer therapy: lessons from the first decade.
Orlowski RZ; Kuhn DJ
Clin Cancer Res; 2008 Mar; 14(6):1649-57. PubMed ID: 18347166
[TBL] [Abstract][Full Text] [Related]
18. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Tobinai K
Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
[No Abstract] [Full Text] [Related]
19. Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
Catley L; Tai YT; Chauhan D; Anderson KC
Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition for treatment of multiple myeloma: clinical update.
Stadtmauer EA
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]